Pour plus de facilité, laissez cette case cochée. Sur les appareils partagés, nous vous conseillons de vous déconnecter d'Euroquity à la fin de votre utilisation
Email

Vous allez recevoir un email pour créer un nouveau mot de passe

Localisation

Choisissez votre pays

et votre langue

Bonjour ,

Bienvenue sur votre profil personnel. Votre carte de visite professionnelle présente votre activité principale. Elle sera visible sur EuroQuity.

% complété

%

medal 2
Ce profil est validé par 2 label.

Company

Protinhi Therapeutics

Protinhi Therapeutics_logo
29
EQ SCORE

L'EQ Score indique l'activité et l'attractivité de l'entreprise sur la plateforme : complétude du profil, actualités, likes, follows, appartenance à un ou plusieurs labels ou communautés, nombre de membres de son réseau, etc.

We are an early-stage biotech company aiming to combat (emerging) viral infectious diseases with a high unmet medical need. With our proprietary technology, we are developing novel antiviral drugs that inhibit proteases and block viral replication.

Nijmegen, Gelderland, Netherlands

Send a message

Anglais

Protinhi Therapeutics

Anglais

Protinhi Therapeutics develops novel drugs acting as protease inhibitors to treat a wide range of illnesses. Currently we focus on viral infectious diseases, including Flaviviridae (e.g., dengue), Chikungunya and Corona virus. Our aim is to make those drugs available as new medication for patients in need of effective treatment.

In viral infectious diseases, protease encoded by virus plays a crutial role in its viral replication after infection of host cells. Protinhi’s innovative...

See more

Protinhi Therapeutics develops novel drugs acting as protease inhibitors to treat a wide range of illnesses. Currently we focus on viral infectious diseases, including Flaviviridae (e.g., dengue), Chikungunya and Corona virus. Our aim is to make those drugs available as new medication for patients in need of effective treatment.

In viral infectious diseases, protease encoded by virus plays a crutial role in its viral replication after infection of host cells. Protinhi’s innovative compounds are inhibitory small molecules which block the protease, and consequentially also the mediated viral replication. The ability to block viral replication empowers our small molecules to be drug candidates not only for therapeutic treatment but also for prophylactic use.

Certifications

Seal of Excellence
The Seal of Excellence is a quality label awarded to project proposals submitted to Horizon 2020 which succeeded a highly competitive evaluation process by independent experts, but did not receive funding due to budget limits. This quality label is a guarantee for investors to find high standard project proposals from European SMEs with growth potential.
1481 Entities
EUREKA Accelerated
Eureka is the world’s leading network for international R&D collaborations, represented in over 45 countries. It aims to boost the growth of SMEs, large companies, research organisations and universities through funding and supporting international R&D cooperation and providing investment-readiness services Through Eureka’s programmes, organisations can access funding and expert support. The Eureka label is given to companies who have been financed through Eureka programmes.
212 Entities

Communities

InvestHorizon
InvestHorizon is an accelerator programme designed to facilitate the access to Series A funding for selected DEEP TECH companies.
1921 Members
Access2EIC – Seal of Excellence
The Access2EIC -Seal of Excellence community aims at gathering high potential European companies that received from the European Commission a “Seal of Excellence” certificate and European equity investors. https://access2eic.eu/
2130 Members